The potential of melanotropins in the treatment of nervous system diseases.
Department of Medical Pharmacology, Rudolf Magnus Institute, Utrecht, The Netherlands.
W H
WH
Gispen
D000324:Adrenocorticotropic Hormone / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology; D002478:Cells, Cultured; D003929:Diabetic Neuropathies / Q000188:drug therapy*; D004195:Disease Models, Animal; D006801:Humans; D009074:Melanocyte-Stimulating Hormones / Q000494:pharmacology / Q000627:therapeutic use*; D009416:Nerve Regeneration / Q000187:drug effects / Q000502:physiology*; D009422:Nervous System Diseases / Q000188:drug therapy*; D009474:Neurons / Q000166:cytology / Q000187:drug effects; D010446:Peptide Fragments / Q000494:pharmacology; D011333:Pro-Opiomelanocortin / Q000096:biosynthesis; D012333:RNA, Messenger / Q000378:metabolism
D000927:Anticonvulsants; D010446:Peptide Fragments; D012333:RNA, Messenger; C013765:Org 2766; D011333:Pro-Opiomelanocortin; D000324:Adrenocorticotropic Hormone; D009074:Melanocyte-Stimulating Hormones